Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis

Inclusion Criteria: * Adult premenopausal females, 18 years and older. * Mentally competent patients that can comply with the study protocol and are able to complete and keep or study related material (patient diaries, etc.). * Signed and dated written informed consent. * Clinical diagnosis of BV according to Amsel criteria * Gram stains Nugent Score ≥7 or Nugent Score 4-6 with the presence of clue cells * Patient does not need an anti-infective treatment which would be required for specific treatment of vaginosis or to prevent the development of acute vaginitis and which may affect treatment outcome of BV. * Negative pregnancy test at screening. Exclusion Criteria: * Patients with other infectious causes of vulvovaginitis (e.g. Vaginal candidiasis, Trichomonas vaginalis). * Patients with another vaginal or vulvar condition, which would confound the interpretation of clinical and or therapeutic response. * Patients who received antifungal or antimicrobial therapy (systemic or intravaginal), as part of standard clinical practice, or clinical trial, within 14 days of randomization. * Patients who are diagnosed with a chronic inflammatory disease (Rheumatoid Arthritis, psoriasis, Crohn's disease, Coeliac disease, spondyloarthritis rheumatica etc.) * Women who are scheduled to be under treatment during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma. * Pregnancy or lactation. * Patients with known hypersensitivity to formaldehyde. * Patients undergoing antibiotic treatment. * Patients with acute polyarthritis, known serious cardiac, liver, kidney diseases or unstable diabetes mellitus. * Known abnormalities of the blood circulation or of the haemopoietic system. * Use of any investigational drug within 30 days from randomization. * Patients who do not abstain from use of intravaginal products for at least 7 days prior to study randomization (e.g. douches, female deodorant sprays, spermicides, condoms, tampons, and diaphragms). Patients should also refrain from using intravaginal products 3 days prior to each study visit. * Patients who do not abstain from vaginal intercourse during at least 3 days prior to each study visit.